Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
After ZW171's exit, ZW251 enters the clinic.
One step forward, two steps back for biotech.
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
Another SERD catalyst and the son of Darzalex take centre stage.
Tough equity markets as well as competitor developments prompt a narrowed focus.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
Giredestrant will soon become the first oral SERD to yield first-line data.
